ID   FRDA_HUMAN              Reviewed;         210 AA.
AC   Q16595; A8MXJ6; C9JJ89; O15545; O95656; Q15294; Q5VZ01;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 2.
DT   18-JUN-2025, entry version 232.
DE   RecName: Full=Frataxin, mitochondrial {ECO:0000303|PubMed:18725397};
DE            EC=1.16.3.1 {ECO:0000269|PubMed:15641778};
DE   AltName: Full=Friedreich ataxia protein;
DE            Short=Fxn;
DE   Contains:
DE     RecName: Full=Frataxin intermediate form;
DE              Short=i-FXN;
DE   Contains:
DE     RecName: Full=Frataxin(56-210);
DE     AltName: Full=m56-FXN;
DE   Contains:
DE     RecName: Full=Frataxin(78-210);
DE     AltName: Full=d-FXN;
DE     AltName: Full=m78-FXN;
DE   Contains:
DE     RecName: Full=Frataxin mature form;
DE     AltName: Full=Frataxin(81-210);
DE     AltName: Full=m81-FXN;
DE   Contains:
DE     RecName: Full=Extramitochondrial frataxin {ECO:0000303|PubMed:20053667};
DE   Flags: Precursor;
GN   Name=FXN {ECO:0000312|HGNC:HGNC:3951}; Synonyms=FRDA, X25;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), ALTERNATIVE
RP   SPLICING, AND VARIANT PHE-154.
RX   PubMed=8596916; DOI=10.1126/science.271.5254.1423;
RA   Campuzano V., Montermini L., Molto M.D., Pianese L., Cossee M.,
RA   Cavalcanti F., Monros E., Rodius F., Duclos F., Monticelli A., Zara F.,
RA   Canizares J., Koutnikova H., Bidichandani S., Gellera C., Brice A.,
RA   Trouillas P., de Michele G., Filla A., de Frutos R., Palau F., Patel P.I.,
RA   di Donato S., Mandel J.-L., Cocozza S., Koenig M., Pandolfo M.;
RT   "Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA
RT   triplet repeat expansion.";
RL   Science 271:1423-1427(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 81-90, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF 39-ARG-ARG-40; 53-ARG-ARG-54; 78-LEU-ARG-79 AND
RP   79-ARG-LYS-80.
RX   PubMed=18725397; DOI=10.1093/hmg/ddn244;
RA   Schmucker S., Argentini M., Carelle-Calmels N., Martelli A., Puccio H.;
RT   "The in vivo mitochondrial two-step maturation of human frataxin.";
RL   Hum. Mol. Genet. 17:3521-3531(2008).
RN   [5]
RP   PROTEIN SEQUENCE OF 81-86, PROTEOLYTIC PROCESSING, MUTAGENESIS OF
RP   53-ARG-ARG-54 AND 79-ARG-LYS-80, AND TISSUE SPECIFICITY.
RX   PubMed=17468497; DOI=10.1093/hmg/ddm102;
RA   Condo I., Ventura N., Malisan F., Rufini A., Tomassini B., Testi R.;
RT   "In vivo maturation of human frataxin.";
RL   Hum. Mol. Genet. 16:1534-1540(2007).
RN   [6]
RP   PROTEIN SEQUENCE OF 81-86, PROTEOLYTIC PROCESSING, FUNCTION, INTERACTION
RP   WITH ACO1, AND SUBCELLULAR LOCATION.
RX   PubMed=20053667; DOI=10.1093/hmg/ddp592;
RA   Condo I., Malisan F., Guccini I., Serio D., Rufini A., Testi R.;
RT   "Molecular control of the cytosolic aconitase/IRP1 switch by
RT   extramitochondrial frataxin.";
RL   Hum. Mol. Genet. 19:1221-1229(2010).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 89-128, AND VARIANT FRDA TYR-122.
RA   Kostrzewa M.;
RL   Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 89-128, AND VARIANT FRDA TYR-122.
RA   Doudney J.D., Pook M.A., Al-Mahdawi S., Carvajal J.J., Hillerman R.,
RA   Chamberlain S.;
RT   "A novel splice site mutation (384+1G-A) in the Friedreich's ataxia gene.";
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 162-210.
RA   Laccone F., Schloesser M.;
RT   "Correct sequence in exon 5a of x25: human frataxin (FRDA),
RT   F175(TTC)-->Y175(TAC) and W202(TGG)-->S202(TCC).";
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9302253; DOI=10.1093/hmg/6.11.1771;
RA   Campuzano V., Montermini L., Lutz Y., Cova L., Hindelang C.,
RA   Jiralerspong S., Trottier Y., Kish S.J., Faucheux B., Trouillas P.,
RA   Authier F.J., Duerr A., Mandel J.-L., Vescovi A., Pandolfo M., Koenig M.;
RT   "Frataxin is reduced in Friedreich ataxia patients and is associated with
RT   mitochondrial membranes.";
RL   Hum. Mol. Genet. 6:1771-1780(1997).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9241270; DOI=10.1038/ng0897-345;
RA   Koutnikova H., Campuzano V., Foury F., Dolle P., Cazzalini O., Koenig M.;
RT   "Studies of human, mouse and yeast homologues indicate a mitochondrial
RT   function for frataxin.";
RL   Nat. Genet. 16:345-351(1997).
RN   [12]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=10545606; DOI=10.1093/hmg/8.12.2255;
RA   Gordon D.M., Shi Q., Dancis A., Pain D.;
RT   "Maturation of frataxin within mammalian and yeast mitochondria: one-step
RT   processing by matrix processing peptidase.";
RL   Hum. Mol. Genet. 8:2255-2262(1999).
RN   [13]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=10428860; DOI=10.1074/jbc.274.32.22763;
RA   Branda S.S., Cavadini P., Adamec J., Kalousek F., Taroni F., Isaya G.;
RT   "Yeast and human frataxin are processed to mature form in two sequential
RT   steps by the mitochondrial processing peptidase.";
RL   J. Biol. Chem. 274:22763-22769(1999).
RN   [14]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=11020385; DOI=10.1074/jbc.m006539200;
RA   Cavadini P., Adamec J., Taroni F., Gakh O., Isaya G.;
RT   "Two-step processing of human frataxin by mitochondrial processing
RT   peptidase. Precursor and intermediate forms are cleaved at different
RT   rates.";
RL   J. Biol. Chem. 275:41469-41475(2000).
RN   [15]
RP   POSSIBLE FUNCTION IN IRON STORAGE, AND SUBUNIT.
RX   PubMed=11823441; DOI=10.1093/hmg/11.3.217;
RA   Cavadini P., O'Neill H.A., Benada O., Isaya G.;
RT   "Assembly and iron-binding properties of human frataxin, the protein
RT   deficient in Friedreich ataxia.";
RL   Hum. Mol. Genet. 11:217-227(2002).
RN   [16]
RP   POSSIBLE FUNCTION IN IRON STORAGE, AND SUBUNIT.
RX   PubMed=12755598; DOI=10.1021/bi027021l;
RA   Nichol H., Gakh O., O'Neill H.A., Pickering I.J., Isaya G., George G.N.;
RT   "Structure of frataxin iron cores: an X-ray absorption spectroscopic
RT   study.";
RL   Biochemistry 42:5971-5976(2003).
RN   [17]
RP   FUNCTION IN IRON-SULFUR CLUSTER BIOSYNTHESIS, AND INTERACTION WITH ISCU.
RX   PubMed=12785837; DOI=10.1021/ja027967i;
RA   Yoon T., Cowan J.A.;
RT   "Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron
RT   donor for assembly of [2Fe-2S] clusters in ISU-type proteins.";
RL   J. Am. Chem. Soc. 125:6078-6084(2003).
RN   [18]
RP   POSSIBLE FUNCTION IN HEME BIOSYNTHESIS, AND INTERACTION WITH FECH.
RX   PubMed=15123683; DOI=10.1074/jbc.c400107200;
RA   Yoon T., Cowan J.A.;
RT   "Frataxin-mediated iron delivery to ferrochelatase in the final step of
RT   heme biosynthesis.";
RL   J. Biol. Chem. 279:25943-25946(2004).
RN   [19]
RP   FUNCTION.
RX   PubMed=15247478; DOI=10.1126/science.1098991;
RA   Bulteau A.L., O'Neill H.A., Kennedy M.C., Ikeda-Saito M., Isaya G.,
RA   Szweda L.I.;
RT   "Frataxin acts as an iron chaperone protein to modulate mitochondrial
RT   aconitase activity.";
RL   Science 305:242-245(2004).
RN   [20]
RP   FUNCTION IN OXIDATIVE STRESS, SUBUNIT, AND CATALYTIC ACTIVITY.
RX   PubMed=15641778; DOI=10.1021/bi048459j;
RA   O'Neill H.A., Gakh O., Park S., Cui J., Mooney S.M., Sampson M.,
RA   Ferreira G.C., Isaya G.;
RT   "Assembly of human frataxin is a mechanism for detoxifying redox-active
RT   iron.";
RL   Biochemistry 44:537-545(2005).
RN   [21]
RP   INTERACTION WITH SDHA AND SDHB.
RX   PubMed=15961414; DOI=10.1093/hmg/ddi214;
RA   Gonzalez-Cabo P., Vazquez-Manrique R.P., Garcia-Gimeno M.A., Sanz P.,
RA   Palau F.;
RT   "Frataxin interacts functionally with mitochondrial electron transport
RT   chain proteins.";
RL   Hum. Mol. Genet. 14:2091-2098(2005).
RN   [22]
RP   FUNCTION, AND INVOLVEMENT IN HEME BIOSYNTHESIS.
RX   PubMed=16239244; DOI=10.1093/hmg/ddi393;
RA   Schoenfeld R.A., Napoli E., Wong A., Zhan S., Reutenauer L., Morin D.,
RA   Buckpitt A.R., Taroni F., Lonnerdal B., Ristow M., Puccio H.,
RA   Cortopassi G.A.;
RT   "Frataxin deficiency alters heme pathway transcripts and decreases
RT   mitochondrial heme metabolites in mammalian cells.";
RL   Hum. Mol. Genet. 14:3787-3799(2005).
RN   [23]
RP   INTERACTION WITH ISCU (ISOFORM 2), SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=16091420; DOI=10.1242/jcs.02516;
RA   Acquaviva F., De Biase I., Nezi L., Ruggiero G., Tatangelo F., Pisano C.,
RA   Monticelli A., Garbi C., Acquaviva A.M., Cocozza S.;
RT   "Extra-mitochondrial localisation of frataxin and its association with
RT   IscU1 during enterocyte-like differentiation of the human colon
RT   adenocarcinoma cell line Caco-2.";
RL   J. Cell Sci. 118:3917-3924(2005).
RN   [24]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=15581888; DOI=10.1016/j.jmb.2004.10.074;
RA   O'Neill H.A., Gakh O., Isaya G.;
RT   "Supramolecular assemblies of human frataxin are formed via subunit-subunit
RT   interactions mediated by a non-conserved amino-terminal region.";
RL   J. Mol. Biol. 345:433-439(2005).
RN   [25]
RP   FUNCTION IN CELL SURVIVAL, AND SUBCELLULAR LOCATION.
RX   PubMed=16608849; DOI=10.1074/jbc.m511960200;
RA   Condo I., Ventura N., Malisan F., Tomassini B., Testi R.;
RT   "A pool of extramitochondrial frataxin that promotes cell survival.";
RL   J. Biol. Chem. 281:16750-16756(2006).
RN   [26]
RP   INTERACTION WITH LYRM4 AND HSPA9, AND CHARACTERIZATION OF VARIANTS PHE-154
RP   AND ARG-155.
RX   PubMed=17331979; DOI=10.1093/hmg/ddm038;
RA   Shan Y., Napoli E., Cortopassi G.;
RT   "Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and
RT   multiple mitochondrial chaperones.";
RL   Hum. Mol. Genet. 16:929-941(2007).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   COMPONENT OF CORE (FE-S) CLUSTER ASSEMBLY COMPLEX, MUTAGENESIS OF GLU-96;
RP   ASP-104; GLU-108; GLU-111; ASP-115; ASP-124; ASN-146 AND TRP-173,
RP   SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND CHARACTERIZATION OF
RP   VARIANTS FRDA TYR-122; VAL-130 AND PHE-154.
RX   PubMed=21298097; DOI=10.1371/journal.pone.0016199;
RA   Schmucker S., Martelli A., Colin F., Page A., Wattenhofer-Donze M.,
RA   Reutenauer L., Puccio H.;
RT   "Mammalian frataxin: an essential function for cellular viability through
RT   an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly
RT   complex.";
RL   PLoS ONE 6:e16199-e16199(2011).
RN   [29]
RP   VARIANTS FRDA PHE-154; ARG-155 AND CYS-165, CHARACTERIZATION OF VARIANTS
RP   FRDA PHE-154; ARG-155 AND CYS-165, AND FUNCTION.
RX   PubMed=24971490; DOI=10.1021/bi500532e;
RA   Bridwell-Rabb J., Fox N.G., Tsai C.L., Winn A.M., Barondeau D.P.;
RT   "Human frataxin activates Fe-S cluster biosynthesis by facilitating sulfur
RT   transfer chemistry.";
RL   Biochemistry 53:4904-4913(2014).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [31]
RP   INTERACTION WITH HSPA9.
RX   PubMed=26702583; DOI=10.1016/j.mito.2015.12.005;
RA   Shan Y., Cortopassi G.;
RT   "Mitochondrial Hspa9/Mortalin regulates erythroid differentiation via iron-
RT   sulfur cluster assembly.";
RL   Mitochondrion 26:94-103(2016).
RN   [32]
RP   INTERACTION WITH THE CYSTEINE DESULFURASE COMPLEX AND ISCU, AND FUNCTION.
RX   PubMed=29576242; DOI=10.1016/j.jinorgbio.2018.03.007;
RA   Cai K., Frederick R.O., Tonelli M., Markley J.L.;
RT   "Interactions of iron-bound frataxin with ISCU and ferredoxin on the
RT   cysteine desulfurase complex leading to Fe-S cluster assembly.";
RL   J. Inorg. Biochem. 183:107-116(2018).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 88-210.
RX   PubMed=10900192; DOI=10.1074/jbc.c000407200;
RA   Dhe-Paganon S., Shigeta R., Chi Y.-I., Ristow M., Shoelson S.E.;
RT   "Crystal structure of human frataxin.";
RL   J. Biol. Chem. 275:30753-30756(2000).
RN   [34]
RP   STRUCTURE BY NMR OF 91-210.
RX   PubMed=10903947; DOI=10.1016/s0969-2126(00)00158-1;
RA   Musco G., Stier G., Kolmerer B., Adinolfi S., Martin S., Frenkiel T.,
RA   Gibson T., Pastore A.;
RT   "Towards a structural understanding of Friedreich's ataxia: the solution
RT   structure of frataxin.";
RL   Structure 8:695-707(2000).
RN   [35] {ECO:0007744|PDB:6NZU}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.20 ANGSTROMS) OF 81-210 IN COMPLEX WITH
RP   ISCU; LYRM4 AND FNS1, SUBUNIT, VARIANTS FRDA ARG-155 AND CYS-165,
RP   CHARACTERIZATION OF VARIANTS FRDA ARG-155 AND CYS-165, AND INTERACTION WITH
RP   ISCU.
RX   PubMed=31101807; DOI=10.1038/s41467-019-09989-y;
RA   Fox N.G., Yu X., Feng X., Bailey H.J., Martelli A., Nabhan J.F.,
RA   Strain-Damerell C., Bulawa C., Yue W.W., Han S.;
RT   "Structure of the human frataxin-bound iron-sulfur cluster assembly complex
RT   provides insight into its activation mechanism.";
RL   Nat. Commun. 10:2210-2210(2019).
RN   [36]
RP   VARIANTS FRDA VAL-130 AND PHE-154.
RX   PubMed=9150176;
RA   Bidichandani S.I., Ashizawa T., Patel P.I.;
RT   "Atypical Friedreich ataxia caused by compound heterozygosity for a novel
RT   missense mutation and the GAA triplet-repeat expansion.";
RL   Am. J. Hum. Genet. 60:1251-1256(1997).
RN   [37]
RP   VARIANT FRDA SER-106.
RX   PubMed=9779809;
RX   DOI=10.1002/(sici)1096-8628(19981012)79:5<396::aid-ajmg13>3.3.co;2-b;
RA   Bartolo C., Mendell J.R., Prior T.W.;
RT   "Identification of a missense mutation in a Friedreich's ataxia patient:
RT   implications for diagnosis and carrier studies.";
RL   Am. J. Med. Genet. 79:396-399(1998).
RN   [38]
RP   VARIANTS FRDA VAL-130; CYS-165 AND PHE-182.
RX   PubMed=10732799; DOI=10.1007/s100480050037;
RA   Forrest S.M., Knight M., Delatycki M.B., Paris D., Williamson R., King J.,
RA   Yeung L., Nassif N., Nicholson G.A.;
RT   "The correlation of clinical phenotype in Friedreich ataxia with the site
RT   of point mutations in the FRDA gene.";
RL   Neurogenetics 1:253-257(1998).
RN   [39]
RP   VARIANTS FRDA TYR-122 AND VAL-130.
RX   PubMed=9989622;
RX   DOI=10.1002/1531-8249(199902)45:2<200::aid-ana10>3.0.co;2-u;
RA   Cossee M., Duerr A., Schmitt M., Dahl N., Trouillas P., Allinson P.,
RA   Kostrzewa M., Nivelon-Chevallier A., Gustavson K.-H., Kohlschuetter A.,
RA   Mueller U., Mandel J.-L., Brice A., Koenig M., Cavalcanti F., Tammaro A.,
RA   de Michele G., Filla A., Cocozza S., Labuda M., Montermini L., Poirier J.,
RA   Pandolfo M.;
RT   "Friedreich's ataxia: point mutations and clinical presentation of compound
RT   heterozygotes.";
RL   Ann. Neurol. 45:200-206(1999).
RN   [40]
RP   VARIANT FRDA ARG-155.
RA   Labuda M., Poirier J., Pandolfo M.;
RT   "A missense mutation (W155R) in an American patient with Friedreich's
RT   ataxia.";
RL   Hum. Mutat. 13:506-506(1999).
RN   [41]
RP   VARIANT FRDA ARG-198.
RX   PubMed=10874325;
RX   DOI=10.1002/1098-1004(200007)16:1<95::aid-humu29>3.0.co;2-e;
RA   Al-Mahdawi S., Pook M., Chamberlain S.;
RT   "A novel missense mutation (L198R) in the Friedreich's ataxia gene.";
RL   Hum. Mutat. 16:95-95(2000).
RN   [42]
RP   CHARACTERIZATION OF VARIANT FRDA PHE-154.
RX   PubMed=19629184; DOI=10.1371/journal.pone.0006379;
RA   Calmels N., Schmucker S., Wattenhofer-Donze M., Martelli A., Vaucamps N.,
RA   Reutenauer L., Messaddeq N., Bouton C., Koenig M., Puccio H.;
RT   "The first cellular models based on frataxin missense mutations that
RT   reproduce spontaneously the defects associated with Friedreich ataxia.";
RL   PLoS ONE 4:E6379-E6379(2009).
CC   -!- FUNCTION: [Frataxin mature form]: Functions as an activator of
CC       persulfide transfer to the scaffoding protein ISCU as component of the
CC       core iron-sulfur cluster (ISC) assembly complex and participates to the
CC       [2Fe-2S] cluster assembly (PubMed:12785837, PubMed:24971490).
CC       Accelerates sulfur transfer from NFS1 persulfide intermediate to ISCU
CC       and to small thiols such as L-cysteine and glutathione leading to
CC       persulfuration of these thiols and ultimately sulfide release
CC       (PubMed:24971490). Binds ferrous ion and is released from FXN upon the
CC       addition of both L-cysteine and reduced FDX2 during [2Fe-2S] cluster
CC       assembly (PubMed:29576242). The core iron-sulfur cluster (ISC) assembly
CC       complex is involved in the de novo synthesis of a [2Fe-2S] cluster, the
CC       first step of the mitochondrial iron-sulfur protein biogenesis. This
CC       process is initiated by the cysteine desulfurase complex
CC       (NFS1:LYRM4:NDUFAB1) that produces persulfide which is delivered on the
CC       scaffold protein ISCU in a FXN-dependent manner. Then this complex is
CC       stabilized by FDX2 which provides reducing equivalents to accomplish
CC       the [2Fe-2S] cluster assembly. Finally, the [2Fe-2S] cluster is
CC       transferred from ISCU to chaperone proteins, including HSCB, HSPA9 and
CC       GLRX5 (By similarity). May play a role in the protection against iron-
CC       catalyzed oxidative stress through its ability to catalyze the
CC       oxidation of Fe(2+) to Fe(3+); the oligomeric form but not the
CC       monomeric form has in vitro ferroxidase activity (PubMed:15641778). May
CC       be able to store large amounts of iron in the form of a ferrihydrite
CC       mineral by oligomerization; however, the physiological relevance is
CC       unsure as reports are conflicting and the function has only been shown
CC       using heterologous overexpression systems (PubMed:11823441,
CC       PubMed:12755598). May function as an iron chaperone protein that
CC       protects the aconitase [4Fe-4S]2+ cluster from disassembly and promotes
CC       enzyme reactivation (PubMed:15247478). May play a role as a high
CC       affinity iron binding partner for FECH that is capable of both
CC       delivering iron to ferrochelatase and mediating the terminal step in
CC       mitochondrial heme biosynthesis (PubMed:15123683, PubMed:16239244).
CC       {ECO:0000250|UniProtKB:Q9H1K1, ECO:0000269|PubMed:11823441,
CC       ECO:0000269|PubMed:12755598, ECO:0000269|PubMed:12785837,
CC       ECO:0000269|PubMed:15123683, ECO:0000269|PubMed:15247478,
CC       ECO:0000269|PubMed:15641778, ECO:0000269|PubMed:16239244,
CC       ECO:0000269|PubMed:24971490, ECO:0000269|PubMed:29576242}.
CC   -!- FUNCTION: [Extramitochondrial frataxin]: Modulates the RNA-binding
CC       activity of ACO1 (PubMed:20053667). May be involved in the cytoplasmic
CC       iron-sulfur protein biogenesis (PubMed:16091420). May contribute to
CC       oxidative stress resistance and overall cell survival
CC       (PubMed:16608849). {ECO:0000269|PubMed:16091420,
CC       ECO:0000269|PubMed:16608849, ECO:0000269|PubMed:20053667}.
CC   -!- CATALYTIC ACTIVITY: [Frataxin mature form]:
CC       Reaction=4 Fe(2+) + O2 + 4 H(+) = 4 Fe(3+) + 2 H2O;
CC         Xref=Rhea:RHEA:11148, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:29033, ChEBI:CHEBI:29034; EC=1.16.3.1;
CC         Evidence={ECO:0000269|PubMed:15641778};
CC   -!- SUBUNIT: [Frataxin mature form]: Component of the mitochondrial core
CC       iron-sulfur cluster (ISC) complex composed of NFS1, LYRM4, NDUFAB1,
CC       ISCU, FXN, and FDX2; this complex is a heterohexamer containing two
CC       copies of each monomer (Probable). Homodimer (PubMed:31101807). Monomer
CC       (probable predominant form). Oligomer. Monomers and polymeric
CC       aggregates of >1 MDa have been isolated from mitochondria. A small
CC       fraction of heterologous overexpressed recombinant frataxin forms high-
CC       molecular weight aggregates that incorporate iron (PubMed:11823441,
CC       PubMed:12755598, PubMed:15581888, PubMed:15641778). Interacts with
CC       LYRM4 (PubMed:17331979). Interacts (via ferrous form) with ISCU; the
CC       interaction is possible when both are bound to the dimeric form of the
CC       cysteine desulfurase complex (NFS1:LYRM4) and the interaction enhances
CC       FXN interaction to the dimeric form of the cysteine desulfurase complex
CC       (NFS1:LYRM4) (PubMed:12785837, PubMed:29576242, PubMed:31101807).
CC       Interacts with FECH; one iron-bound FXN monomer seems to interact with
CC       a FECH homodimer (PubMed:15123683). Interacts with SDHA and SDHB
CC       (PubMed:15961414). Interacts with ACO2; the interaction is dependent on
CC       citrate (By similarity). Interacts with HSPA9 (PubMed:17331979,
CC       PubMed:26702583). {ECO:0000250|UniProtKB:D3ZYW7,
CC       ECO:0000269|PubMed:11823441, ECO:0000269|PubMed:12755598,
CC       ECO:0000269|PubMed:12785837, ECO:0000269|PubMed:15123683,
CC       ECO:0000269|PubMed:15581888, ECO:0000269|PubMed:15641778,
CC       ECO:0000269|PubMed:15961414, ECO:0000269|PubMed:17331979,
CC       ECO:0000269|PubMed:26702583, ECO:0000269|PubMed:29576242,
CC       ECO:0000269|PubMed:31101807, ECO:0000305|PubMed:21298097,
CC       ECO:0000305|PubMed:31101807}.
CC   -!- SUBUNIT: [Extramitochondrial frataxin]: Interacts with ACO1
CC       (PubMed:20053667). Interacts with ISCU (cytoplasmic form)
CC       (PubMed:16091420). {ECO:0000269|PubMed:16091420,
CC       ECO:0000269|PubMed:20053667}.
CC   -!- INTERACTION:
CC       Q16595; Q9BVU5: ARL17; NbExp=3; IntAct=EBI-949340, EBI-25857117;
CC       Q16595; Q9HC96: CAPN10; NbExp=3; IntAct=EBI-949340, EBI-3915761;
CC       Q16595; Q92828: CORO2A; NbExp=3; IntAct=EBI-949340, EBI-2835660;
CC       Q16595; Q9UN19: DAPP1; NbExp=6; IntAct=EBI-949340, EBI-3918199;
CC       Q16595; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-949340, EBI-5916454;
CC       Q16595; O75925: PIAS1; NbExp=3; IntAct=EBI-949340, EBI-629434;
CC       Q16595; Q9NS23-4: RASSF1; NbExp=3; IntAct=EBI-949340, EBI-438710;
CC       Q16595; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-949340, EBI-749039;
CC       Q16595; Q96D59: RNF183; NbExp=3; IntAct=EBI-949340, EBI-743938;
CC       Q16595; Q8N6K7-2: SAMD3; NbExp=3; IntAct=EBI-949340, EBI-11528848;
CC       Q16595; Q9GZS3: SKIC8; NbExp=3; IntAct=EBI-949340, EBI-358545;
CC   -!- SUBCELLULAR LOCATION: [Frataxin mature form]: Mitochondrion
CC       {ECO:0000269|PubMed:15581888, ECO:0000269|PubMed:16091420,
CC       ECO:0000269|PubMed:16608849, ECO:0000269|PubMed:18725397,
CC       ECO:0000269|PubMed:20053667, ECO:0000269|PubMed:21298097,
CC       ECO:0000269|PubMed:9241270, ECO:0000269|PubMed:9302253}.
CC   -!- SUBCELLULAR LOCATION: [Extramitochondrial frataxin]: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:16091420, ECO:0000269|PubMed:16608849,
CC       ECO:0000269|PubMed:20053667}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q16595-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16595-2; Sequence=VSP_001576;
CC       Name=3;
CC         IsoId=Q16595-3; Sequence=VSP_047282;
CC   -!- TISSUE SPECIFICITY: Expressed in the heart, peripheral blood
CC       lymphocytes and dermal fibroblasts. {ECO:0000269|PubMed:17468497}.
CC   -!- PTM: Processed in two steps by mitochondrial processing peptidase
CC       (MPP). MPP first cleaves the precursor to intermediate form and
CC       subsequently converts the intermediate to yield frataxin mature form
CC       (frataxin(81-210)) which is the predominant form (PubMed:21298097). The
CC       additional forms, frataxin(56-210) and frataxin(78-210), seem to be
CC       produced when the normal maturation process is impaired; their
CC       physiological relevance is unsure. {ECO:0000269|PubMed:10428860,
CC       ECO:0000269|PubMed:10545606, ECO:0000269|PubMed:11020385,
CC       ECO:0000269|PubMed:17468497, ECO:0000269|PubMed:18725397,
CC       ECO:0000269|PubMed:21298097}.
CC   -!- DISEASE: Friedreich ataxia (FRDA) [MIM:229300]: Autosomal recessive,
CC       progressive degenerative disease characterized by neurodegeneration and
CC       cardiomyopathy it is the most common inherited ataxia. The disorder is
CC       usually manifest before adolescence and is generally characterized by
CC       incoordination of limb movements, dysarthria, nystagmus, diminished or
CC       absent tendon reflexes, Babinski sign, impairment of position and
CC       vibratory senses, scoliosis, pes cavus, and hammer toe. In most
CC       patients, FRDA is due to GAA triplet repeat expansions in the first
CC       intron of the frataxin gene. But in some cases the disease is due to
CC       mutations in the coding region. {ECO:0000269|PubMed:10732799,
CC       ECO:0000269|PubMed:10874325, ECO:0000269|PubMed:19629184,
CC       ECO:0000269|PubMed:21298097, ECO:0000269|PubMed:24971490,
CC       ECO:0000269|PubMed:31101807, ECO:0000269|PubMed:9150176,
CC       ECO:0000269|PubMed:9779809, ECO:0000269|PubMed:9989622,
CC       ECO:0000269|Ref.40, ECO:0000269|Ref.7, ECO:0000269|Ref.8}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: The unusual migration profile of mature frataxin on SDS-
CC       PAGE due to its acidic N-terminus most likely contributed to
CC       conflicting reports for the N-terminus of the mature protein. Unlike
CC       prokaryotic and yeast frataxin homologs, which self-assemble at high
CC       iron concentrations, oligomerization of human frataxin is not induced
CC       by iron. The existence of a specialized mitochondrial ferritin in
CC       mammalia (FTMT) is suggesting that iron storage would be redundant
CC       function, at least in mammalian mitochondria.
CC   -!- MISCELLANEOUS: [Isoform 2]: Not highly expressed and may be
CC       artifactual. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the frataxin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U43747; AAA98510.1; -; mRNA.
DR   EMBL; U43752; AAA98508.1; -; Genomic_DNA.
DR   EMBL; U43748; AAA98508.1; JOINED; Genomic_DNA.
DR   EMBL; U43749; AAA98508.1; JOINED; Genomic_DNA.
DR   EMBL; U43750; AAA98508.1; JOINED; Genomic_DNA.
DR   EMBL; U43751; AAA98508.1; JOINED; Genomic_DNA.
DR   EMBL; U43753; AAA98509.1; -; Genomic_DNA.
DR   EMBL; U43748; AAA98509.1; JOINED; Genomic_DNA.
DR   EMBL; U43749; AAA98509.1; JOINED; Genomic_DNA.
DR   EMBL; U43750; AAA98509.1; JOINED; Genomic_DNA.
DR   EMBL; U43751; AAA98509.1; JOINED; Genomic_DNA.
DR   EMBL; AL162730; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC023633; AAH23633.1; -; mRNA.
DR   EMBL; BC048097; AAH48097.1; -; mRNA.
DR   EMBL; Y13751; CAA74077.1; -; Genomic_DNA.
DR   EMBL; AF028240; AAB84047.1; -; Genomic_DNA.
DR   EMBL; U93173; AAD00734.1; -; Genomic_DNA.
DR   CCDS; CCDS43834.1; -. [Q16595-3]
DR   CCDS; CCDS6626.1; -. [Q16595-1]
DR   RefSeq; NP_000135.2; NM_000144.4. [Q16595-1]
DR   RefSeq; NP_001155178.1; NM_001161706.1.
DR   RefSeq; NP_852090.1; NM_181425.3. [Q16595-3]
DR   PDB; 1EKG; X-ray; 1.80 A; A=86-210.
DR   PDB; 1LY7; NMR; -; A=91-210.
DR   PDB; 3S4M; X-ray; 1.30 A; A=82-210.
DR   PDB; 3S5D; X-ray; 1.50 A; A=82-210.
DR   PDB; 3S5E; X-ray; 1.31 A; A=82-210.
DR   PDB; 3S5F; X-ray; 1.50 A; A/B=82-210.
DR   PDB; 3T3J; X-ray; 1.70 A; A=82-210.
DR   PDB; 3T3K; X-ray; 1.24 A; A=82-210.
DR   PDB; 3T3L; X-ray; 1.15 A; A=82-210.
DR   PDB; 3T3T; X-ray; 1.38 A; A/B/C/D=82-210.
DR   PDB; 3T3X; X-ray; 1.57 A; A/B=82-210.
DR   PDB; 5KZ5; EM; 14.30 A; A/B/C/D/E/F/G/H/I/J/K/L=42-210.
DR   PDB; 6NZU; EM; 3.20 A; I/J=81-210.
DR   PDB; 8PK8; EM; 2.49 A; E=81-210.
DR   PDB; 8PK9; EM; 2.58 A; E=81-210.
DR   PDB; 8RME; EM; 2.49 A; I=81-210.
DR   PDBsum; 1EKG; -.
DR   PDBsum; 1LY7; -.
DR   PDBsum; 3S4M; -.
DR   PDBsum; 3S5D; -.
DR   PDBsum; 3S5E; -.
DR   PDBsum; 3S5F; -.
DR   PDBsum; 3T3J; -.
DR   PDBsum; 3T3K; -.
DR   PDBsum; 3T3L; -.
DR   PDBsum; 3T3T; -.
DR   PDBsum; 3T3X; -.
DR   PDBsum; 5KZ5; -.
DR   PDBsum; 6NZU; -.
DR   PDBsum; 8PK8; -.
DR   PDBsum; 8PK9; -.
DR   PDBsum; 8RME; -.
DR   AlphaFoldDB; Q16595; -.
DR   BMRB; Q16595; -.
DR   EMDB; EMD-0560; -.
DR   EMDB; EMD-17732; -.
DR   EMDB; EMD-17733; -.
DR   EMDB; EMD-19359; -.
DR   EMDB; EMD-8301; -.
DR   SASBDB; Q16595; -.
DR   SMR; Q16595; -.
DR   BioGRID; 108677; 57.
DR   ComplexPortal; CPX-5641; Mitochondrial NIAUFX iron-sulfur cluster assembly complex.
DR   CORUM; Q16595; -.
DR   FunCoup; Q16595; 974.
DR   IntAct; Q16595; 23.
DR   MINT; Q16595; -.
DR   STRING; 9606.ENSP00000419243; -.
DR   ChEMBL; CHEMBL2321640; -.
DR   DrugBank; DB14490; Ferrous ascorbate.
DR   DrugBank; DB14491; Ferrous fumarate.
DR   DrugBank; DB14488; Ferrous gluconate.
DR   DrugBank; DB14501; Ferrous glycine sulfate.
DR   DrugBank; DB14489; Ferrous succinate.
DR   DrugBank; DB01592; Iron.
DR   TCDB; 9.B.21.1.1; the frataxin (frataxin) family.
DR   iPTMnet; Q16595; -.
DR   PhosphoSitePlus; Q16595; -.
DR   BioMuta; FXN; -.
DR   OGP; Q16595; -.
DR   jPOST; Q16595; -.
DR   MassIVE; Q16595; -.
DR   PaxDb; 9606-ENSP00000366482; -.
DR   PeptideAtlas; Q16595; -.
DR   ProteomicsDB; 2327; -.
DR   ProteomicsDB; 60939; -. [Q16595-1]
DR   ProteomicsDB; 60940; -. [Q16595-2]
DR   Pumba; Q16595; -.
DR   TopDownProteomics; Q16595-1; -. [Q16595-1]
DR   TopDownProteomics; Q16595-2; -. [Q16595-2]
DR   ABCD; Q16595; 1 sequenced antibody.
DR   Antibodypedia; 26793; 657 antibodies from 35 providers.
DR   DNASU; 2395; -.
DR   Ensembl; ENST00000396366.6; ENSP00000379652.2; ENSG00000165060.15. [Q16595-3]
DR   Ensembl; ENST00000484259.3; ENSP00000419243.2; ENSG00000165060.15. [Q16595-1]
DR   GeneID; 2395; -.
DR   KEGG; hsa:2395; -.
DR   MANE-Select; ENST00000484259.3; ENSP00000419243.2; NM_000144.5; NP_000135.2.
DR   UCSC; uc004agz.3; human. [Q16595-1]
DR   AGR; HGNC:3951; -.
DR   CTD; 2395; -.
DR   DisGeNET; 2395; -.
DR   GeneCards; FXN; -.
DR   GeneReviews; FXN; -.
DR   HGNC; HGNC:3951; FXN.
DR   HPA; ENSG00000165060; Low tissue specificity.
DR   MalaCards; FXN; -.
DR   MIM; 229300; phenotype.
DR   MIM; 606829; gene.
DR   OpenTargets; ENSG00000165060; -.
DR   Orphanet; 95; Friedreich ataxia.
DR   VEuPathDB; HostDB:ENSG00000165060; -.
DR   eggNOG; KOG3413; Eukaryota.
DR   GeneTree; ENSGT00390000005811; -.
DR   HOGENOM; CLU_080880_1_0_1; -.
DR   InParanoid; Q16595; -.
DR   OMA; QSVHLMN; -.
DR   OrthoDB; 1897642at2759; -.
DR   PAN-GO; Q16595; 8 GO annotations based on evolutionary models.
DR   PhylomeDB; Q16595; -.
DR   PathwayCommons; Q16595; -.
DR   Reactome; R-HSA-1268020; Mitochondrial protein import.
DR   Reactome; R-HSA-1362409; Mitochondrial iron-sulfur cluster biogenesis.
DR   Reactome; R-HSA-9854311; Maturation of TCA enzymes and regulation of TCA cycle.
DR   Reactome; R-HSA-9865881; Complex III assembly.
DR   SABIO-RK; Q16595; -.
DR   SignaLink; Q16595; -.
DR   SIGNOR; Q16595; -.
DR   BioGRID-ORCS; 2395; 504 hits in 1139 CRISPR screens.
DR   ChiTaRS; FXN; human.
DR   EvolutionaryTrace; Q16595; -.
DR   GeneWiki; Frataxin; -.
DR   GenomeRNAi; 2395; -.
DR   Pharos; Q16595; Tbio.
DR   PRO; PR:Q16595; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q16595; protein.
DR   Bgee; ENSG00000165060; Expressed in right lobe of liver and 181 other cell types or tissues.
DR   ExpressionAtlas; Q16595; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:1990229; C:iron-sulfur cluster assembly complex; NAS:ComplexPortal.
DR   GO; GO:0099128; C:mitochondrial [2Fe-2S] assembly complex; IDA:UniProtKB.
DR   GO; GO:0005759; C:mitochondrial matrix; ISS:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0051537; F:2 iron, 2 sulfur cluster binding; IDA:BHF-UCL.
DR   GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL.
DR   GO; GO:0008199; F:ferric iron binding; IDA:BHF-UCL.
DR   GO; GO:0008198; F:ferrous iron binding; IDA:UniProtKB.
DR   GO; GO:0004322; F:ferroxidase activity; IDA:UniProtKB.
DR   GO; GO:0034986; F:iron chaperone activity; IDA:BHF-UCL.
DR   GO; GO:0044571; P:[2Fe-2S] cluster assembly; IDA:UniProtKB.
DR   GO; GO:0044572; P:[4Fe-4S] cluster assembly; IDA:UniProtKB.
DR   GO; GO:0007628; P:adult walking behavior; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:UniProtKB.
DR   GO; GO:0009792; P:embryo development ending in birth or egg hatching; IEA:Ensembl.
DR   GO; GO:0006783; P:heme biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0006879; P:intracellular iron ion homeostasis; IMP:BHF-UCL.
DR   GO; GO:0006826; P:iron ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0016226; P:iron-sulfur cluster assembly; IDA:BHF-UCL.
DR   GO; GO:0034551; P:mitochondrial respiratory chain complex III assembly; TAS:Reactome.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0046621; P:negative regulation of organ growth; IEA:Ensembl.
DR   GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; IMP:UniProtKB.
DR   GO; GO:0035265; P:organ growth; IEA:Ensembl.
DR   GO; GO:0006119; P:oxidative phosphorylation; IEA:Ensembl.
DR   GO; GO:0051349; P:positive regulation of lyase activity; IDA:UniProtKB.
DR   GO; GO:0019230; P:proprioception; IEA:Ensembl.
DR   GO; GO:0016540; P:protein autoprocessing; IDA:BHF-UCL.
DR   GO; GO:0051604; P:protein maturation; IMP:BHF-UCL.
DR   GO; GO:0010039; P:response to iron ion; IMP:BHF-UCL.
DR   CDD; cd00503; Frataxin; 1.
DR   DisProt; DP00607; -.
DR   FunFam; 3.30.920.10:FF:000002; Frataxin, mitochondrial; 1.
DR   Gene3D; 3.30.920.10; Frataxin/CyaY; 1.
DR   InterPro; IPR017789; Frataxin.
DR   InterPro; IPR002908; Frataxin/CyaY.
DR   InterPro; IPR036524; Frataxin/CyaY_sf.
DR   InterPro; IPR020895; Frataxin_CS.
DR   NCBIfam; TIGR03421; FeS_CyaY; 1.
DR   NCBIfam; TIGR03422; mito_frataxin; 1.
DR   PANTHER; PTHR16821; FRATAXIN; 1.
DR   PANTHER; PTHR16821:SF4; FRATAXIN, MITOCHONDRIAL; 1.
DR   Pfam; PF01491; Frataxin_Cyay; 1.
DR   PRINTS; PR00904; FRATAXIN.
DR   SMART; SM01219; Frataxin_Cyay; 1.
DR   SUPFAM; SSF55387; Frataxin/Nqo15-like; 1.
DR   PROSITE; PS01344; FRATAXIN_1; 1.
DR   PROSITE; PS50810; FRATAXIN_2; 1.
DR   neXtProt; NX_Q16595; -.
DR   PharmGKB; PA28369; -.
DR   TreeFam; TF318958; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Direct protein sequencing;
KW   Disease variant; Heme biosynthesis; Ion transport; Iron; Iron storage;
KW   Iron transport; Metal-binding; Mitochondrion; Oxidoreductase;
KW   Proteomics identification; Reference proteome; Transit peptide; Transport;
KW   Triplet repeat expansion.
FT   TRANSIT         1..41
FT                   /note="Mitochondrion"
FT   CHAIN           42..210
FT                   /note="Frataxin intermediate form"
FT                   /id="PRO_0000010129"
FT   CHAIN           56..210
FT                   /note="Frataxin(56-210)"
FT                   /id="PRO_0000010130"
FT   CHAIN           78..210
FT                   /note="Frataxin(78-210)"
FT                   /id="PRO_0000399388"
FT   CHAIN           81..210
FT                   /note="Extramitochondrial frataxin"
FT                   /id="PRO_0000456947"
FT   CHAIN           81..210
FT                   /note="Frataxin mature form"
FT                   /id="PRO_0000289331"
FT   VAR_SEQ         161..210
FT                   /note="SGPKRYDWTGKNWVYSHDGVSLHELLAAELTKALKTKLDLSSLAYSGKDA
FT                   -> RLTWLLWLFHP (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8596916"
FT                   /id="VSP_001576"
FT   VAR_SEQ         161..210
FT                   /note="SGPKRYDWTGKNWVYSHDGVSLHELLAAELTKALKTKLDLSSLAYSGKDA
FT                   -> RYVVDLSVMTGLGKTGCTPTTACPSMSCWPQSSLKP (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_047282"
FT   VARIANT         106
FT                   /note="L -> S (in FRDA; dbSNP:rs104894105)"
FT                   /evidence="ECO:0000269|PubMed:9779809"
FT                   /id="VAR_016065"
FT   VARIANT         122
FT                   /note="D -> Y (in FRDA; does not affect interaction with
FT                   the core iron-sulfur cluster assembly complex; does not
FT                   affect mitochondrial localization; does not affect
FT                   proteolytic processing; dbSNP:rs142157346)"
FT                   /evidence="ECO:0000269|PubMed:21298097,
FT                   ECO:0000269|PubMed:9989622, ECO:0000269|Ref.7,
FT                   ECO:0000269|Ref.8"
FT                   /id="VAR_002428"
FT   VARIANT         130
FT                   /note="G -> V (in FRDA; does not affect interaction with
FT                   the core iron-sulfur cluster assembly complex; does not
FT                   affect mitochondrial localization; does not affect
FT                   proteolytic processing.; dbSNP:rs104894107)"
FT                   /evidence="ECO:0000269|PubMed:10732799,
FT                   ECO:0000269|PubMed:21298097, ECO:0000269|PubMed:9150176,
FT                   ECO:0000269|PubMed:9989622"
FT                   /id="VAR_002429"
FT   VARIANT         154
FT                   /note="I -> F (in FRDA; reduces interaction with the core
FT                   iron-sulfur cluster assembly complex; does not affect
FT                   mitochondrial localization; does not affect proteolytic
FT                   processing; reduces interaction with LYRM4; the interaction
FT                   is rescued by nickel; a murine cellular FRDA model, deleted
FT                   for endogenous frataxin and expressing human mutant
FT                   frataxin cDNA shows defects in mitochondrial structure,
FT                   mitochondrial iron deposits, decreased enzymatic activity
FT                   of some mitochondrial and cytoplasmic iron-sulfur
FT                   cluster-containing enzymes, increased RNA-binding activity
FT                   of ACO1 and increased sensitivity to oxidative stress;
FT                   decreases the level of covalent incorporation of sulfur
FT                   into both NFS1 and ISCU; dbSNP:rs104894106)"
FT                   /evidence="ECO:0000269|PubMed:17331979,
FT                   ECO:0000269|PubMed:19629184, ECO:0000269|PubMed:21298097,
FT                   ECO:0000269|PubMed:24971490, ECO:0000269|PubMed:8596916,
FT                   ECO:0000269|PubMed:9150176"
FT                   /id="VAR_087120"
FT   VARIANT         155
FT                   /note="W -> R (in FRDA; reduces interaction with LYRM4; the
FT                   interaction is rescued by nickel; drastically decreases
FT                   affinity for the SDAU complex by > 75-fold; decreases the
FT                   level of covalent incorporation of sulfur into both NFS1
FT                   and ISCU; dbSNP:rs138471431)"
FT                   /evidence="ECO:0000269|PubMed:17331979,
FT                   ECO:0000269|PubMed:24971490, ECO:0000269|PubMed:31101807,
FT                   ECO:0000269|Ref.40"
FT                   /id="VAR_087121"
FT   VARIANT         165
FT                   /note="R -> C (in FRDA; mild form; decreases affinity for
FT                   the SDAU complex by 40-fold; decreases the level of
FT                   covalent incorporation of sulfur into both NFS1 and ISCU;
FT                   dbSNP:rs138034837)"
FT                   /evidence="ECO:0000269|PubMed:10732799,
FT                   ECO:0000269|PubMed:24971490, ECO:0000269|PubMed:31101807"
FT                   /id="VAR_087122"
FT   VARIANT         182
FT                   /note="L -> F (in FRDA; dbSNP:rs139616452)"
FT                   /evidence="ECO:0000269|PubMed:10732799"
FT                   /id="VAR_008140"
FT   VARIANT         198
FT                   /note="L -> R (in FRDA; dbSNP:rs144104124)"
FT                   /evidence="ECO:0000269|PubMed:10874325"
FT                   /id="VAR_016066"
FT   VARIANT         202
FT                   /note="S -> C (in dbSNP:rs1052195)"
FT                   /id="VAR_049100"
FT   MUTAGEN         39..40
FT                   /note="RR->GG: Abolishes cleavage to yield frataxin
FT                   intermediate form and allows accumulation of
FT                   frataxin(56-210) and frataxin(78-210)."
FT                   /evidence="ECO:0000269|PubMed:18725397"
FT   MUTAGEN         53..54
FT                   /note="RR->GG: No effect on processing of wild-type FXN."
FT                   /evidence="ECO:0000269|PubMed:17468497,
FT                   ECO:0000269|PubMed:18725397"
FT   MUTAGEN         78..79
FT                   /note="LR->GG: Abolishes cleavage to yield frataxin mature
FT                   form and allows accumulation of frataxin(56-210) and
FT                   frataxin(78-210)."
FT                   /evidence="ECO:0000269|PubMed:18725397"
FT   MUTAGEN         79..80
FT                   /note="RK->GG: Abolishes cleavage to yield frataxin mature
FT                   form and allows the accumulation of frataxin(56-210)."
FT                   /evidence="ECO:0000269|PubMed:17468497,
FT                   ECO:0000269|PubMed:18725397"
FT   MUTAGEN         96
FT                   /note="E->K: Does not affect interaction with the core
FT                   iron-sulfur cluster assembly complex. Does not affect
FT                   mitochondrial localization. Does not affect proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:21298097"
FT   MUTAGEN         104
FT                   /note="D->G: Does not affect interaction with the core
FT                   iron-sulfur cluster assembly complex. Does not affect
FT                   mitochondrial localization. Does not affect proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:21298097"
FT   MUTAGEN         108
FT                   /note="E->K: Significantly reduces interaction with the
FT                   core iron-sulfur cluster assembly complex. Does not affect
FT                   mitochondrial localization. Does not affect proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:21298097"
FT   MUTAGEN         111
FT                   /note="E->K: Significantly reduces interaction with the
FT                   core iron-sulfur cluster assembly complex. Does not affect
FT                   mitochondrial localization. Does not affect proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:21298097"
FT   MUTAGEN         115
FT                   /note="D->K: Does not affect interaction with the core
FT                   iron-sulfur cluster assembly complex. Does not affect
FT                   mitochondrial localization. Does not affect proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:21298097"
FT   MUTAGEN         124
FT                   /note="D->K: Drasticly reduces interaction with the core
FT                   iron-sulfur cluster assembly complex. Does not affect
FT                   mitochondrial localization. Does not affect proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:21298097"
FT   MUTAGEN         146
FT                   /note="N->A: Does not affect interaction with the core
FT                   iron-sulfur cluster assembly complex. Does not affect
FT                   mitochondrial localization. Does not affect proteolytic
FT                   processing."
FT                   /evidence="ECO:0000269|PubMed:21298097"
FT   MUTAGEN         173
FT                   /note="W->G: Loss of interaction with the core iron-sulfur
FT                   cluster assembly complex. Does not affect mitochondrial
FT                   localization. Does not affect proteolytic processing."
FT                   /evidence="ECO:0000269|PubMed:21298097"
FT   CONFLICT        175
FT                   /note="Y -> F (in Ref. 1; AAA98508/AAA98510)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        202
FT                   /note="S -> W (in Ref. 1; AAA98508/AAA98510)"
FT                   /evidence="ECO:0000305"
FT   HELIX           92..114
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   STRAND          124..128
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   STRAND          131..135
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   STRAND          138..140
FT                   /evidence="ECO:0007829|PDB:6NZU"
FT   STRAND          142..148
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   TURN            149..152
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   STRAND          153..157
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   STRAND          159..161
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   STRAND          164..168
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   STRAND          170..175
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   TURN            176..178
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   HELIX           182..194
FT                   /evidence="ECO:0007829|PDB:3T3L"
FT   STRAND          203..205
FT                   /evidence="ECO:0007829|PDB:6NZU"
FT   STRAND          206..208
FT                   /evidence="ECO:0007829|PDB:1LY7"
SQ   SEQUENCE   210 AA;  23135 MW;  ECC81738779308CF CRC64;
     MWTLGRRAVA GLLASPSPAQ AQTLTRVPRP AELAPLCGRR GLRTDIDATC TPRRASSNQR
     GLNQIWNVKK QSVYLMNLRK SGTLGHPGSL DETTYERLAE ETLDSLAEFF EDLADKPYTF
     EDYDVSFGSG VLTVKLGGDL GTYVINKQTP NKQIWLSSPS SGPKRYDWTG KNWVYSHDGV
     SLHELLAAEL TKALKTKLDL SSLAYSGKDA
//
